DESMOPRESSIN ACETATE

Post-LOE

desmopressin acetate

Ferring Pharmaceuticals

ANDAORALTABLET

Approved

Jan 2019

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

DESMOPRESSIN ACETATE (desmopressin acetate) by Ferring Pharmaceuticals is clinical pharmacology desmopressin acetate tablets contain as active substance, desmopressin acetate, a synthetic analogue of the natural hormone arginine vasopressin. Approved for primary nocturnal enuresis. First approved in 2019.

Drug data last refreshed 20h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Desmopressin acetate tablets contain as active substance, desmopressin acetate, a synthetic analogue of the natural hormone arginine vasopressin. Central Diabetes Insipidus Dose response studies in patients with diabetes insipidus have demonstrated that oral doses of 0.025 mg…

Worked on DESMOPRESSIN ACETATE at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

DESMOPRESSIN ACETATE

Mechanism of Action

Indications (1)

Clinical Trials (1)